RESEARCH ARTICLE

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells

Tao Yan-Fang1*, Li Zhi-Heng1*, Xu Li-Xiao1*, Fang Fang1, Lu Jun1, Li Gang1, Cao Lan1, Wang Na-Na1, Du Xiao-Juan2, Sun Li-Chao3, Zhao He1, Su Guang-Hao1, Li Yan-Hong1, Li Yi-Ping1, Xu Yun-Yun1, Zhou Hui-Ting1, Wu Yi1, Jin Mei-Fang1, Liu Lin1, Ni Jian4, Hu Shao-Yan1, Zhu Xue-Ming1, Feng Xing3, Wang Jian1*, Pan Jian1*

1 Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China, 2 Department of Gastroenterology, the 5th Hospital of Chinese PLA, Yin chuan, China, 3 Department of Cell and Molecular Biology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 4 Translational Research Center, Second Hospital, The Second Clinical School, Nanjing Medical University, Nanjing, China

☯ These authors contributed equally to this work.
* panjian2008@163.com (PJ); wj196312@vip.163.com (WJ)

Abstract

Background

Wilms tumor (WT) is an embryonic kidney cancer, for which histone acetylation might be a therapeutic target. LBH589, a novel targeted agent, suppresses histone deacetylases in many tumors. This study investigated the antitumor activity of LBH589 in SK-NEP-1 and G401 cells.

Methods

SK-NEP-1 and G401 cell growth was assessed by CCK-8 and in nude mice experiments. Annexin V/propidium iodide staining followed by flow cytometry detected apoptosis in cell culture. Gene expressions of LBH589-treated tumor cells were analyzed using an Arraystar Human LncRNA Array. The Multi Experiment View cluster software analyzed the expression data. Differentially expressed genes from the cluster analyses were imported into the Ingenuity Pathway Analysis tool.

Results

LBH589 inhibited cell proliferation of SK-NEP-1 and G401 cells in a dose-dependent manner. Annexin V, TUNEL and Hoechst 33342 staining analysis showed that LBH589-treated cells showed more apoptotic features compared with the control. LBH589 treatment inhibited the growth of SK-NEP-1 xenograft tumors in nude mice. Arraystar Human LncRNA Array analysis of genes and lncRNAs regulated by LBH589 identified 6653 mRNAs and
8135 IncRNAs in LBH589-treated SK-NEP-1 cells. The most enriched gene ontology terms were those involved in nucleosome assembly. KEGG pathway analysis identified cell cycle proteins, including CCNA2, CCNB2, CCND1, CCND2, CDK4, CDKN1B and HDAC2, etc. Ingenuity Pathway Analysis identified important upstream molecules: HIST2H3C, HIST1H4A, HIST1A, HIST1C, HIST1D, histone H1, histone H3, RPRM, HSP70 and MYC.

Conclusions
LBH589 treatment caused apoptosis and inhibition of cell proliferation of SK-NEP-1 and G401 cells. LBH589 had a significant effect and few side effects on SK-NEP-1 xenograft tumors. Expression profiling, and GO, KEGG and IPA analyses identified new targets and a new "network" of genes responding to LBH589 treatment in SK-NEP-1 cells. RPRM, HSP70 and MYC may be important regulators during LBH589 treatment. Our results provide new clues to the proapoptotic mechanism of LBH589.

Introduction
Wilms tumor (WT) is an embryonic cancer of the kidney composed of blastemal, stromal and epithelial elements. WT is also the most common malignant neoplasm of the urinary tract in children [1]. The overall 5-year survival is estimated as > 80% [4]; however, for individuals, the prognosis is highly dependent on individual staging and treatment. Although WT is almost curable, with long-term survival, the combination of chemotherapy, radiotherapy and surgery often results in severe complications in adulthood [2]. Therefore, decreases the treatment burden and improve outcome of patients are still required [3]. We evaluated the efficacy of LBH589, a histone deacetylases (HDACs) pan inhibitor to inhibit WT development in vitro and in vivo.

HDACs are a large family of enzymes involved in chromatin remodeling that have crucial roles in numerous biological processes, largely through repressing transcription [4–6]. For its importance in regulating gene expression, histone acetylation is now being investigated as therapeutic targets [7–9]. Different HDAC inhibitors induce cell death of cancer cells with different mechanisms, including alterations of both histone and non-histone proteins and changes in gene expression [10, 11]. 2–10% of important biological processes genes were changed when inhibition of HDACs [12]. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression [13, 14]. Recently, HDACs have received increasing attention because HDAC-inhibiting compounds are being developed as promising anti cancer therapeutics.

Several structurally diverse inhibitors for HDACs which have been developed as anti cancer therapeutic agents in vitro and in vivo, they cause differentiation, cell cycle arrest or apoptosis [15–19]. Maintenance growth of cell and differentiation is very highly dependent on tight and coordinated transcriptional regulation of genes. Recently, research has led to the development of HDAC inhibitors as novel anticancer agents. In addition to their effect on epigenetic mechanisms, HDAC inhibitors also can change the acetylation state of many cellular proteins involved in oncogenic processes, resulting in antitumor effects [20–23].

HDAC inhibitor LBH589 has demonstrated antitumor activity, including HDACs suppression and induction of tumor cell apoptosis in various human cancer models. In Triple-negative breast cancer (TNBC), LBH589 has anti-proliferative properties in aggressive breast cancer refractory to hormonal therapy [24]. In human renal cell carcinoma, LBH589 caused obvious
cell cycle arrest in the G2/M phase and caused cell apoptosis [25]. In prostate cancer, the combined treatment of LBH589 and radiation therapy induced more apoptosis and led to a steady increase of sub-G1 population and abolishment of radiation therapy-induced G2/M arrest [26]. In the deadliest skin cancer, melanoma, low nanomolar concentration of LBH589 inhibited the growth of all melanoma cell lines [27]. Treatment of high-risk neuroblastoma cell lines with LBH589 resulted in dose-dependent growth arrest and apoptosis [28]. In hepatocellular carcinoma, LBH589 significantly inhibited HCC growth and metastasis in vitro and in vivo [29]. In oral squamous cell carcinoma, LBH589 induces apoptosis through regulation of specificity protein 1 (Sp1) in oral squamous cell carcinoma cell lines. LBH589 significantly reduced cell growth and the sub-G1 cell population and induced apoptosis [30]. In cisplatin resistance ovarian cancer, a combination of cisplatin and LBH589 could overcome cisplatin-associated resistance in ovarian cancer cells, in the presence of low-dose LBH589 [31]. In small-cell lung cancer (SCLC), multicenter, nonrandomized, phase 2 trials were designed to evaluate the antitumor activity of LBH589 in patients with previously treated SCLC. Modest clinical activity of LBH589 combined with a favorable safety profile in pretreated SCLC patients was observed [32].

Until now, there has been no report of an antitumor effect of LBH589 in WT. The aim of this study was to analyze the antitumor effect and molecular function of LBH589 in human WT cells and in xenograft models.

Materials and Methods

Cell and culture conditions

SK-NEP-1 and G401 Human kidney (Wilm’s Tumor) cell line obtained from the American Type Culture Collection (ATCC) was maintained in the Maccyo’s (Life Technologies Inc., Gaithersburg, MD, USA) supplemented with 20% heat-inactivated fetal bovine serum (Invitrogen Co., NY, USA) in a humidified incubator with 5% CO2 at 37°C. LBH589 (Cat: S1030 Selleck Chemicals, West Paterson, NJ, USA) was dissolved in DMSO (Cat: D4540 Sigma–Aldrich, St. Louis, MO, USA)

Cell proliferation

Cell proliferation analysis was introduced before [3]. SK-NEP-1 and G401 cells (2 × 10⁴) were seeded in 96-well plates overnight and incubated with DMSO, 1 nM LBH589, or increasing concentrations of LBH589 (0.01–10.0 μM) for 24 hours. The same volume of DMSO was added to the vehicle treated wells. Each drug concentration was performed at least in four replicate wells. Then, 10 μL CCK8 (Cell Counting Kit-8: CK04-13, Dojindo Molecular Technologies, Inc. Minato-ku, Tokyo; JAPAN) solution was added to each well, incubated at 37°C for 4 h and the optical density (OD) values were measured at 450 nm using a scanning multi-well spectrophotometer (Bio Rad Model 550, Hercules, California; USA). Compared with control group, relative survival rate was calculated from the absorbance values. Cell proliferation was calculated as a percentage of the DMSO- treated control wells with 50% inhibitory concentration (IC50) values derived after plotting proliferation values on a logarithmic curve. The IC50 of LBH589 inhibitor was calculated by Graph Prism software.

Cell cycle analysis

Cell cycle analysis was introduced before [3]. Briefly, cells were collected and washed for 5 minutes with PBS by centrifugation at 125 × g. Then, cells were fixed with paraformaldehyde and permeabilized with 0.5% Triton X-100. Next, cells were resuspended in staining solution, 1.5 μmol/L propidium iodide (P4170, Sigma–Aldrich, St. Louis, MO, USA) and 25 μg/ml
RNase A and incubated at 37°C for half a hour. The samples (1 ×10^4 cells) were analyzed by flow cytometry with a Beckman Gallios Flow Cytometer.

**Apoptosis assay**

Apoptosis assay was introduced before [3]. Cellular apoptosis assay was according to the manufactory of BD Annexin V Staining Kit (Cat: 556420, BD Biosciences, Franklin Lakes, NJ USA). Briefly, cells were washed twice with cold PBS and then resuspend in 1× binding buffer at concentration of about 1 ×10^6 cells/ml. Then 100 μl of the solution (~1 ×10^5 cells) was transferred to a 5 ml culture tube. Annexin V and PI 5 μl/test was added. Cells were gently mixed and incubated at RT in the dark for 15 min. Then 400 μl of 1× binding buffer was added to each tube. Cells were analyzed by flow cytometry within 1 hour.

**Western blot analysis**

Western blot analysis was introduced before [3]. Cellular proteins were extracted in 40 mM Tris–HCl (pH 7.4) containing 150 mM NaCl and 1% (v/v) Triton X-100, supplemented with protease inhibitors. Equal amounts of protein were resolved on 12% SDS-PAGE gels, and then transferred to a PVDF membrane (Millipore, Bedford, MA). Blots were blocked and then probed with antibodies against Caspase 3 (1:1000, Cell Signaling Technology, Inc. Danvers, MA), PARP (1:1000, Cell Signaling Technology, Inc. Danvers, MA), PRPM(1:1000, GTX110976, GeneTex, Inc. Irvine, CA, USA), c-Myc (1:1000, Cell Signaling Technology, Inc. Danvers, MA), PRKCA (1:1000, BOSTER, Wuhan, China), DNAJA3(1:1000, GeneTex, Inc. Irvine, CA, USA), acetyl-Histone H3 (Lys9) (1:1000, Cell Signaling Technology, Inc. Danvers, MA), acetyl-Histone H4 (Lys8) (1:1000, Cell Signaling Technology, Inc. Danvers, MA), BCL2 (1:1000, Abcam Trading (Shanghai) Company Ltd. Pudong, Shanghai, China), Caspase 9 (1:1000, Cell Signaling Technology, Inc. Danvers, MA), Histone H3(1:1000, Santa Cruz Biotechnology, Inc. Dallas, Texas, USA) and GAPDH (1:5000, Sigma, St. Louis, MO). After three times’ washing, blots were then incubated with horseradish peroxidase (HRP) conjugated secondary antibodies and visualized by enhanced chemiluminescence kit (Pierce, Rockford, IL). Protein bands were visualized after exposure of the membrane to Kodak X-ray film.

**Hoechst 33342 staining analysis**

Cells were seeded into 6-well plates and then treated with LBH589 (50nM or 100nM) and cultured at 37°C for 24 hours, stained with 0.1 μg/ml Hoechst 33342 (Sigma, St. Louis, MO, USA) for 5 min, then observed with filters for blue fluorescence under fluorescence microscopy (OLYMPUS IX71; Olympus Corporation, Tokyo, Japan). Abnormal nuclear cells were counted between the LBH589 treatment group and DMSO control group.

**Analysis of apoptosis by TUNEL assay**

TUNEL is a common method which can detect DNA fragmentation. DNA double-strand breaks happened late in the apoptotic cells and can be assessed using the TUNEL Apoptosis Detection Kit (Cat: KGA704; Kengent, Nanjing, China). TUNEL analysis was introduced
Mechanism of LBH589-Induced Cell Death in Wilms Tumor
Apoptotic cells were photographed by fluorescence microscopy (OLYMPUS IX71; Olympus Corporation, Tokyo, Japan).

**Xenograft assays the treatment effect of LBH589 in nude mice**

We carried out this study strictly accordant with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol has been approved by the Committee on the Ethics of Animal Experiments of Soochow university (Permit Number: 2013-05-03). The mouse study was ended when tumor growth to sizes up to 4000mm³. 1×10⁶ SK-NEP-1 cells were subcutaneously injected into five nude mice every group. 10 days after injection, mice were treated with PBS, DMSO, and LBH589 10mg/kg and 20mg/kg dose three times per week. And the treatment last six weeks. During the six weeks these mice were examined for subcutaneous tumor growth and health condition three times per week. The tumor volumes were calculated according to this formula: volume = length × width²/2. After the last treatment, the mice were killed under sodium pentobarbital anesthesia and the tumor weight was measured.

**Analyze the genes and LncRNAs related with LBH589 treatment with LncRNA array (Arraystar Human LncRNA ArrayV3.0)**

SK-NEP-1 cells were treated with 100nM LBH589 and control group cells were treated with the same volume of DMSO 24 hours later. Human LncRNA Array analysis was performed by KangChen Bio-tech, Shanghai P.R. China. And experimental details were introduced by Yu et al [34]. Briefly, RNA purified from total RNA after removal of rRNA was amplified and transcribed into fluorescent cRNA and cDNA was labeled and hybridized to the Human LncRNA Array v3.0 (8660 K, Arraystar). 30,586 LncRNAs and 26,109 coding transcripts which collected from the most authoritative databases such as RefSeq, UCSC, Knowngenes, Ensembl and many related literatures can be detected by the microarray.

**Gene ontology analysis and KEGG pathway analysis**

Gene ontology (GO) analysis functionally analyze the differentially expressed genes with GO categories which were derived from Gene Ontology (http://david.abcc.ncifcrf.gov/summary.jsp). Pathway analysis of the differentially expressed genes was performed based on the latest Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg). We performed ontologic pathway enrichment analysis for the differently expressed genes and gene product enrichment with particular attention to GO biological processes and molecular function (P-value ≤ 0.05).

**Ingenuity pathway analysis (IPA)**

Our datasets representing genes with altered expression profile derived from array analyses were imported into the Ingenuity Pathway Analysis Tool (IPA Tool; Ingenuity H Systems, Redwood City, CA, USA; http://www.ingenuity.com).
Mechanism of LBH589-Induced Cell Death in Wilms Tumor

A

SK-NEP-1

G401

B

SK-NEP-1

G401

C

SK-NEP-1

G401

D

SK-NEP-1

G401
IPA analysis was introduced before [3]. IPA Tool allows the identification of biological networks, global functions and functional pathways of a particular dataset.

**Real-time PCR analysis certification of dyes-regulated genes in LBH589-treated SK-NEP-1 cells**

Quantitative real-time PCR was performed to determine the expression levels of dyes-regulated genes in LBH589-treated SK-NEP-1 cells. Real-time PCR analysis was introduced before [3]. cDNA synthesis was performed on 4 ug of RNA in a 10 ul sample volume using SuperScript II reverse transcriptase (Invitrogen Co., NY, USA) as recommended by the manufacturer. Reactions were run on Light cycler 480 using the universal thermal cycling parameters. The real time PCR primers used to quantify GAPDH expression were: F: 5'- AGAAGGCTGGGGCTCA TTTG-3' and R: 5'- AGGGGCATCCACAGTCTTC-3'; RPRM were: F: 5'- GCATGAGGACTTTCAGAGGG-3' and R: 5'- GCAAACCTGTCGGAGTCAAT -3'; DHRS2 were: F: 5'- CTCCATGTAGGCGACCACT-3' and R: 5'- GTAGGGAGCACTCTGGGGAC-3'; DNAJA3 were: F: 5'- TGTGGAAGGAGGCAGTACAA -3' and R: 5'- TGCGTCTTCCCTGACCTCT -3'; STMN2 were: F: 5'- CCGGTAAAAGCAAGAGCAGA-3' and R: 5'- CCGGTAAAAGCAAGAGCAGA-3'; PRKACA were: F: 5'- ATCCAAGTGGGCTGTGTTCT-3' and R: 5'- GAGTGATGGCTTCCAACTCC -3'; PAM were: F: 5'- GAAGGCTTCCTCATCCACTG -3' and R: 5'- TTTTGGCATTGGATATTCGCA -3'; PTPN7 were: F: 5'- TCGGAATGTAGTTGGCATTGA-3' and R: 5'- GCATGAGGACTTTCAGAGGG-3'; EIF2AK2 were: F: 5'- ACTTGGCCAAATCCA CCGTCCTGACCTCTG -3' and R: 5'- CCTCCAAGGACCGATACAAG -3'. Expression of genes was normalized to endogenous GAPDH expression.

**Statistical analysis**

Each experimental condition was performed two or three times, and these replicates were presented in results. All values are presented as means ± SEM. Student’s paired t-test was applied to reveal statistical significances. P values less than 0.05 were considered significant. Statistical analyses were performed using SPSS Software for Windows (version 11.5; SPSS, Inc., Chicago, IL).

**Results and Discussion**

**Growth inhibitory effect of LBH589 on SK-NEP-1 and G401 cells**

LBH589 treatment resulted in inhibition of cell proliferation of SK-NEP-1 and G401 cells in a dose-dependent manner (Fig 1A and 1B). The IC₅₀ of LBH589 for SK-NEP-1 cells was 76.34 nM and for G401 was 143.02 nM. The morphology of SK-NEP-1 and G401 cells changed significantly under LBH589-treatment for 48 hours at concentrations of 50nM and 100nM (Fig 1C). Proliferation analysis showed that LBH589 treatment significantly inhibited cell proliferation (Fig 1D). A CCK-8 assay showed that the inhibition rate at 5 days post-treatment was 81.4 ± 8.21% in SK-NEP-1 cells and 83.1 ± 6.6% G401 cells compared with the DMSO control.
Mechanism of LBH589-Induced Cell Death in Wilms Tumor

A

|     | DAPI | TUNEL | Merge |
|-----|------|-------|-------|
| Positive | ![Image](image1) | ![Image](image2) | ![Image](image3) |
| Negative | ![Image](image4) | ![Image](image5) | ![Image](image6) |
| Parent | ![Image](image7) | ![Image](image8) | ![Image](image9) |
| DMSO | ![Image](image10) | ![Image](image11) | ![Image](image12) |
| LBH589 50nM | ![Image](image13) | ![Image](image14) | ![Image](image15) |
| LBH589 100nM | ![Image](image16) | ![Image](image17) | ![Image](image18) |

B

- **SK-NEP-1**
  - Parent: ![Image](image19) ± 5.0%
  - DMSO: ![Image](image20) ± 5.0%
  - 50 nM LBH589: ![Image](image21) ± 20.0%
  - 100 nM LBH589: ![Image](image22) ± 20.0%

- **G401**
  - Parent: ![Image](image23) ± 5.0%
  - DMSO: ![Image](image24) ± 5.0%
  - 50 nM LBH589: ![Image](image25) ± 15.0%
  - 100 nM LBH589: ![Image](image26) ± 20.0%

**Note:** The images are placeholders and should be replaced with actual images from the document.
group ($P < 0.01$). Fig 1E showed that cell survival was significantly reduced when SK-NEP-1 and G401 cells treated with 50nM LBH589 for 1–4 days.

**LBH589 induced apoptosis in SK-NEP-1 and G401 cells**

To confirm whether LBH589 induces apoptosis in SK-NEP-1 and G401 cells, we used Annexin V, cell cycle, tunnel and Hochest33342 assays, and activation of PARP in SK-NEP-1 and G401 cells after LBH589 treatment. The result showed that among cells treated with LBH589 50nM and 100nM for 24 hours, more cells showed apoptotic feature compared with control group, for both SK-NEP-1 and G401 cells (Fig 2A and 2B). The proportion of apoptotic cells in the LBH589-treated cells was significantly greater than that in the DMSO control group: SK-NEP-1 (100nM 26.2% ± 4.45% vs. DMSO 0.97% ± 0.62%, respectively; $P = 0.009$); and G401 (100nM 18.17% ± 0.90% vs. DMSO1.53 ± 0.67%, respectively; $P = 0.001$). Cell late apoptosis was also analyzed (Fig 2C and 2D), and the results showed significant apoptosis in SK-NEP-1 (100nM 14.83% ± 1.55% vs. DMSO 2.30% ± 0.92%, respectively; $P = 0.001$); and G401 cells (100nM 13.23% ± 1.79% vs. DMSO1.67 ± 0.67%, respectively; $P = 0.003$).

Hoechst 33342 staining analysis showed DNA fragmentation and cells with abnormal nuclei after 24 hours of LBH589 treatment (Fig 3A). The number of cells with abnormal nuclei increased significantly compared with control group in both SK-NEP-1 (100nM 13.4% ± 3.99% vs. DMSO 7.81% ± 0.59%, respectively; $P = 0.035$) and G401 cells (100nM 14.73% ± 3.09% vs. DMSO1.47% ± 0.57%, respectively; $P = 0.046$) (Fig 3D). TUNEL staining analysis showed more TUNEL positive cells in the LBH589 treatment groups (Fig 4A). Fig 4B shows the percentages of TUNEL positive cells in SK-NEP-1 (100nM 19.87% ± 3.19% vs. DMSO 2.20% ± 1.99%, respectively; $P = 0.003$); and G401 (100nM 16.53% ± 2.86% vs. DMSO2.40 ± 1.67%, respectively; $P = 0.004$) cells.

To clearly demonstrate that LBH589 causes apoptosis in SK-NEP-1 and G401 cells, we assessed the expression of PARP, caspase 3, caspase 9 and Bcl-2, recognized markers of apoptosis by western blotting. Down regulation of Bcl-2, cleaved PARP and caspase 9 was observed after 24 hours of treatment with 50nM and 100nM LBH589 (Fig 5A). This result is consistent with the data of Annexin V assay and the cell cycle analysis, demonstrating that LBH589 induced apoptosis in SK-NEP-1 and G401 cells. The results suggested that LBH589 has promising antitumor activity against SK-NEP-1 and G401 cells.

**LBH589 treatment inhibited the growth of SK-NEP-1 xenograft tumors in nude mice**

The inhibition impact of LBH589 on the growth of SK-NEP-1 cells in nude mice was assessed. Each group, five nude mice were subcutaneously injected with SK-NEP-1 cells. Our results showed that LBH589 significantly inhibited the growth of SK-NEP-1 xenografts (LBH589
10mg/kg: 1.89 ± 0.77 cm³; LBH589 20mg/kg: 1.14 ± 0.55 cm³) compared with DMSO group (DMSO: 3.01 ± 2.4 cm³, ANOVA P < 0.01 Fig 5B and 5C). LBH589 treatment decreased the weight of the tumors (LBH589 10mg/kg: 1.12 ± 0.36 g; LBH589 20mg/kg: 0.59 ± 0.11 g) compared to DMSO group (DMSO: 2.04 ± 0.29 g) or PBS group (PBS: 1.98 ± 0.31 g, ANOVA P < 0.01). (D) Tumor weight of the treatment experiment. LBH589 treatment decreased the weight of the tumors (LBH589 10mg/kg: 1.12 ± 0.36 g; LBH589 20mg/kg: 0.59 ± 0.11 g) compared to DMSO group (DMSO: 2.04 ± 0.29 g) or PBS group (PBS: 1.98 ± 0.31 g, ANOVA P < 0.01). We also observed that the body mass curve of nude mice treated with LBH589 were almost the same as the control group. At the end of the experiment, body weights of nude mice treated with LBH589 were almost same as the control group (LBH589 10mg/kg: 20.42 ± 2.43g; LBH589 20mg/kg: 20.56 ± 2.34g) compared with the DMSO group (DMSO: 21.44 ± 2.37g) or PBS group cells (PBS: 21.10 ± 1.39g, ANOVA P >0.05). These studies support the view that LBH589 has significant role and few side effects in the treatment of SK-NEP-1 xenograft tumors.

Microarray analysis of differentially expressed genes in LBH589-treated SK-NEP-1 cells

The Arraystar_Human_LncRNA_8x60k v3.01 microarray was used to identify differentially expressed genes and IncRNAs in LBH589-treated SK-NEP-1 cells compared with DMSO-treated control cells. We have submitted our microarray analysis to the GEO repository and assigned GEO accession number is GSE64975.

In the IncRNA/mRNA expression profiling data, we identified 6653 differently expressed mRNAs in LBH589-treated SK-NEP-1 cells (Fig 6A, S1 Dataset and S2 Dataset). Compared with DMSO-treated control cells, 664 mRNAs were significantly up regulated and 632 mRNAs were significantly down regulated > 5 fold changes in LBH589-treated SK-NEP-1 cells. Clustering analysis was used to visualize the relationships between the mRNA expression patterns present in the samples (fold changes ≥ 5; Fig 6B). In the IncRNA expression profiling data, we analyzed a total of 33327 IncRNAs expressed in SK-NEP-1 cells, of which 8135 were differentially expressed in LBH589-treated SK-NEP-1 cells (Fig 6C, S3 Dataset and S4 Dataset). Hierarchical clustering analysis of the differentially expressed IncRNAs with a fold change ≥ 5-fold is presented in Fig 6D.

Gene ontology and KEGG Pathway analysis of differentially expressed mRNAs in LBH589-treated SK-NEP-1 cells

We performed ontological pathway enrichment analysis for the differently expressed genes and gene product enrichment with particular attention to GO biological processes and molecular function. Biological processes enrichment analysis was performed using the DAVID tool to gain insights into their functions. The most enriched GOs targeted by the up regulated and down regulated transcripts were involved in a variety of functions including nucleosome assembly, chromatin assembly, cellular metabolic process and cellular macromolecule metabolic (Fig 7A and 7B). The most significant Cellular component (CC) Enrichment scores are
Mechanism of LBH589-Induced Cell Death in Wilms Tumor

A

B

C

D
shown in Fig 7C and 7D, and the most significant Molecular function (MF) Enrichment scores are shown in Fig 7E and 7F.

The KEGG database was used to investigate the pathways in which the differentially expressed genes are involved. KEGG annotations of the most enriched pathways are shown in Fig 7G, with a p value of 7.48007E-05. Specifically, the significant pathways included cell cycle, p53 signaling pathway and apoptosis. The cell cycle pathway included proteins such as CCNA2, CCNB2, CCND1, CCND2, CDK4, CDKN1B and HDAC2 (S5 Dataset).

Ingenuity pathway analysis of differentially expressed mRNAs in LBH589-treated SK-NEP-1 cells

To investigate the possible biological interactions of the proteins encoded by the differentially regulated genes, datasets representing genes with altered expression profiles derived from microarray analyses were imported into the Ingenuity Pathway Analysis Tool. Ingenuity Pathway Knowledge Base (IPKB) is derived from known functions and interactions of genes or proteins published. The list of differentially expressed genes analyzed by IPA revealed significant networks. Fig 8 represents the highest rated network using the up regulated genes in LBH589-treated SK-NEP-1 cells. Fig 9 represents the highest rated network using down regulated genes in LBH589-treated SK-NEP-1 cells. IPA analysis showed that the important upstream molecules included HIST2H3C, HIST1H4A, HIST1A, HIST1C, HIST1D, Histone H1, Histone H3, RPRM, HSP70 and MYC. These upstream regulators such as Histone H1, Histone H3 and the Histone family have already been reported as important regulators for LBH589 treatment. Histones have been widely investigated and are important targets of LBH589. However, there has been no report about the relationship between RPRM, HSP70, MYC and LBH589. This work is the first time to indicate that RPRM, HSP70 and MYC may be important regulators during LBH589 treatment. Thus, these results provide new clues to the molecular mechanism of apoptosis induced by LBH589.

Real-time PCR and western blot analysis validation of the apoptosis-regulated genes in LBH589-treated SK-NEP-1 cells

To validate the expressions of apoptosis-regulated genes in LBH589-treated SK-NEP-1 cells, we analyzed the expression of eight apoptosis-regulated genes in LBH589-treated SK-NEP-1 cells: RPRM, DHR52, DNAJA3, STMN2, PRKACA, PAM, PTPN7 and EIF2AK2. Fig 10A showed that the qRT-PCR analysis results were consistent with the microarray analysis. Western blot analysis showed that LBH589 induces hyperacetylation of histone H3K9 and H4K8, and down regulates the expression of c-MYC. Western blot analysis also validated the apoptosis-regulated genes PRKCA, RPRM and DNAJA3 in LBH589-treated SK-NEP-1 cells (Fig 10B).

Up to 90% of Wilms tumor patients can be cured with current therapy, but there is still need to improve therapy for aggressive patients [35]. Various HDACs have been reported involved in different functions and pathways in cells. HDACs expression levels vary in different kinds of...
Mechanism of LBH589-Induced Cell Death in Wilms Tumor

A: nucleosome assembly, chromatin assembly, response to cadmium ion, protein-DNA complex assembly, cell projection organization, regulation of catalytic activity, nervous system development, nucleosome organization, actin filament bundle assembly, cellular process

B: cellular metabolic process, cellular macromolecule metabolic primary metabolic process, cellular nitrogen metabolic process, nucleobase-containing metabolic process, nitrogen metabolic process, macromolecule metabolic process, nucleic acid metabolic process, cellular process

C: enzyme regulator activity, kinase regulator activity, protein kinase regulator activity, transferase activity, kinase inhibitor activity, kinase activity, protein kinase inhibitor activity, delayed rectifier potassium channel activity, apoptotic protease activator, ATPase activity

D: protein binding, RNA binding, small molecule binding, binding, nucleotide binding, transcription cofactor activity, nucleic acid binding, protein binding transcription factor binding, chromatin binding

E: Systemic lupus erythematosus, Alcoholism, Viral carcinogenesis, Rheumatoid arthritis, Dopaminergic synapse, Proximal tubule bicarbonate transport, Intestinal immune network, Collecting duct acid secretion, Type 1 diabetes mellitus, Pancreatic secretion

F: cell cycle, p53 signaling pathway, apoptosis, DNA replication, pyrimidine metabolism, measles, One carbon pool, herpes simplex infection, transcription misregulation, cysteine methionine metabolism

G: Cell Cycle Diagram

Figure G: Cell Cycle Diagram. Diagram showing the stages of the cell cycle: G1, S, G2, and M, with various regulatory factors and checkpoints indicated. The diagram includes DNA damage checkpoints, apoptosis, and various cellular processes and proteins.
cancer cells. HDAC1 has been reported over expressed in gastric and prostate cancers. In lung, colon, esophageal and breast cancers high expression of HDAC1 also indicates poor prognosis. High expression level of HDAC2 was also reported in cervical, colorectal and gastric cancers [36–38]. HDAC3 has also been reported over expressed in prostate, gastric and colorectal cancer patients [39–41]. Over expression of HDAC8 in neuroblastoma correlates with metastasis and poor prognosis. Expression level of HDAC11 is also up regulated in rhabdomyosarcoma [42–44]. The present study indicated that HDACs are also important targets for human wilms tumor cells.

Several structurally diverse HDAC inhibitors have been developed as cancer therapeutic agents and have been shown to cause differentiation, cell cycle arrest, or apoptosis in vitro [15]. Now, there are over 490 clinical trials for cancer to investigate the clinical application of HDAC inhibitors. Vorinostat (suberoylanilide hydroxamic acid, SAHA), the first HDAC inhibitor for refractory and relapsed cutaneous T-cell lymphoma (CTCL) has been approved by FDA [45, 46]. LBH589 is a novel pan HDACs inhibitor that possesses potent growth inhibitory activity in Ph(-) ALL cells [47], triple-negative breast cancer (TNBC)[24], hepatocellular carcinoma [29], prostate cancer (PCa) cells [48], relapsed/refractory Waldenstrom macroglobulinemia (WM) [49] and multiple myeloma (MM) [50]. However, to date, the molecular function of LBH589 in WT has remained unknown.

Our results indicated that LBH589 treatment caused inhibition of cell proliferation of SK-NEP-1 and G401 cells in a dose-dependent manner. Cells treated with LBH589 showed more apoptotic feature and abnormal nuclei compared with the control group. In the LBH589 treatment group the G2 phase was significantly down regulated, there were more TUNEL positive cells and cleaved PARP, caspase 9 were observed. These results demonstrated for the first time that LBH589 induced apoptosis in SK-NEP-1 and G401 cells. Our research also indicated that LBH589 treatment inhibits the growth of SK-NEP-1 xenograft tumors in nude mice.

These results supported the view that LBH589 has a significant role and few side effects in the treatment of SK-NEP-1 xenograft tumors. In this study, we analyzed the apoptosis-regulated genes by LBH589 using the Arraystar Human LncRNA Array. LncRNA/mRNA expression profiling data identified 6653 differentially expressed mRNAs in LBH589-treated SK-NEP-1 cells. 8135 lncRNAs were differentially expressed in LBH589-treated SK-NEP-1 cells. This is the first report of lncRNA/mRNA expression profiling related to LBH589 treatment in SK-NEP-1 cells. Our research will focus on the molecule function of these LBH589-related lncRNAs.

Ontological pathway enrichment analysis showed the most enriched GOs targeted by the up regulated and down regulated transcripts were involved in a variety of functions including nucleosome assembly, chromatin assembly, cellular metabolic process and cellular macromolecule metabolic. KEGG pathway annotations of the most enriched pathways identified the cell cycle-related proteins, such as CCNA2, CCNB2, CCND1, CCND2, CDK4, CDKN1B, HDAC2, etc.
the hyperacetylation function of LBH589 in WT cells. However, our results also indicated that RPRM, HSP70 and MYC might be important regulators during LBH589 treatment. Reprimo (RPRM), initially identified as a downstream effector of p53-induced cell cycle arrest at G2/M, is a putative tumor suppressor gene that is silenced via promoter methylation in several types of human cancer [51–54]. In 83 primary human gastric cancer tissues, RPRM gene promoter
methylation was cancer-specific and frequently observed. Enforced RPRM expression robustly inhibited cell proliferation and anchorage-independent colony formation, as well as enhanced DNA damage-induced apoptosis [55]. RPRM may be a new target of LBH589, and our result also implied a new network for LBH589 for the first time.

Fig 9. Ingenuity Pathways Analysis (IPA) summary of down regulated genes in SK-NEP-1 cells treated with LBH589. To investigate possible interactions of differently regulated genes, datasets representing down regulated genes in SK-NEP-1 cells treated with LBH589 were imported into the Ingenuity Pathway Analysis Tool. The following data are shown: most highly rated network in IPA analysis. The network representation of the most highly rated network. Statistical analysis determined that the shaded genes are significant. A solid line represents a direct interaction between the two gene products and a dotted line means there is an indirect interaction.

doi:10.1371/journal.pone.0126566.g009
Conclusions

The present study demonstrated that LBH589 treatment resulted in apoptosis and inhibition of cell proliferation of SK-NEP-1 and G401 cells. LBH589 had a significant role and few side effects in the treatment of SK-NEP-1 xenograft tumors. Arraystar Human LncRNA Array analysis provided the expression profile of lncRNAs/mRNAs in LBH589-treated SK-NEP-1 cells. GO, KEGG and IPA analysis identified new targets and network affected by LBH589 treatment. RPRM, HSP70 and MYC may be important regulators during the LBH589 treatment. The results may provide new clues to the molecular mechanism of apoptosis induced by LBH589.

Supporting Information

S1 Dataset. Differentially Expressed mRNAs upregulated in SK-NEP-1 cells treated with LBH589.
(XLS)

S2 Dataset. Differentially Expressed mRNAs downregulated in SK-NEP-1 cells treated with LBH589.
(XLS)

S3 Dataset. Differentially Expressed LncRNAs upregulated in SK-NEP-1 cells treated with LBH589.
(XLS)

S4 Dataset. Differentially expressed LncRNAs downregulated in SK-NEP-1 cells treated with LBH589.
(XLS)

S5 Dataset. Summary of KEGG analysis the differentially expressed mRNAs in SK-NEP-1 cells treated with LBH589.
(XLS)

Author Contributions

Wrote the paper: PJ. Designed and directed the study: PJ WJ. Finished most of the experiments: LJ LZH FF. Finished the real-time PCR array: TYF XLX. Finished the IC50 analysis of LBH589: LG CL WNN. Supported the design of primer for RT-PCR: DXJ SLC. Finished the apoptosis assay: LYP XYY. Finished the western blot analysis: ZHT WY JMF LL. Finished the cell cycle analysis: ZH, SGH. Drafted the manuscript: ZWL XPF. Participated in study design and coordination, data analysis and interpretation, and drafted the manuscript: LYH HSY ZXM FX NJ.

References

1. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatric blood & cancer. 2008; 50(3):703–6. Epub 2006/12/13. doi: 10.1002/pbc.21099 PMID: 17154184.
2. Davenport KP, Bianco FC, Sandler AD. Pediatric malignancies: neuroblastoma, Wilm’s tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. Surg Clin North Am. 92(3):745–67, x. PMID: 22595719. doi:10.1016/j.suc.2012.03.004

3. Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NP-1 Wimls tumor cells. BMC cancer. 2012; 12:619. Epub 2012/12/27. doi: 10.1186/1471-2407-12-619 PMID: 23267699; PubMed Central PMCID: PMC3543843.

4. Bahari-Javan S, Maddalena A, Kerimoglu C, Wittnam J, Held T, Bahr M, et al. HDAC1 regulates fear extinction in mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012; 32(15):5062–73. Epub 2012/04/13. doi: 10.1523/JNEUROSCI.0779-12.2012 PMID: 22496552.

5. Bellucci L, Dalvai M, Kocanova S, Moutahir F, Bystricky K. Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PloS one. 2013; 8(1):e54102. Epub 2013/01/26. doi:10.1371/journal.pone.0054102 PMID: 23349794; PubMed Central PMCID: PMC3548890.

6. Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA. HDAC inhibitors in kidney development and disease. Pediatr Nephrol. 2013; 28(10):1909–21. Epub 2012/10/12. doi: 10.1007/s00467-012-2320-8 PMID: 23052657; PubMed Central PMCID: PMC3751322.

7. Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011–2013). Expert opinion on therapeutic patents. 2014; 24(4):401–15. Epub 2014/01/09. doi: 10.1517/13543776.2014.877446 PMID: 24397271.

8. Ren J, Zhang J, Cai H, Li Y, Zhang Y, Zhang X, et al. HDAC as a therapeutic target for treatment of endometrial cancers. Current pharmaceutical design. 2014; 20(11):1847–56. Epub 2013/07/31. PMID: 23888962.

9. Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Current drug targets. 2014; 15(6):622–34. Epub 2014/03/07. PMID: 24597570.

10. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014. Epub 2014/06/15. PMID:25115382.

11. Juengel E, Nowaz S, Makarevi J, Natsheh I, Werner I, Nelson K, et al. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Molecular cancer. 2014; 13:152. Epub 2014/06/18. doi: 10.1186/1476-4598-13-152 PMID: 24935000; PubMed Central PMCID: PMC4073177.

12. Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014; 158(2):161–9. Epub 2014/07/31. doi:10.5507/bp.2013.085 PMID: 24263215.

13. Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, et al. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. Journal of nuclear medicine: Official publication, Society of Nuclear Medicine. 2014; 55(4):678–85. Epub 2014/03/19. doi: 10.2967/jnumed.113.126573 PMID: 24659460.

14. Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, Atadja P, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-kappaB/STAT3 complex to its promoter in malignant lymphoid cells. Cell death & disease. 2013; 4:e635. Epub 2013/05/18. doi: 10.1038/cddis.2013.159 PMID: 23681230; PubMed Central PMCID: PMC3751366.

15. Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(1):223–34. Epub 2006/01/07. doi: 10.1158/1078-0432.CCR-05-1225 PMID: 16397046.

16. Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, et al. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. International journal of oncology. 2014; 44(2):451–8. Epub 2013/12/04. doi: 10.3892/ijo.2013.2193 PMID: 24297449.

17. Yan SF, You HJ, Xing TY, Zhang CG, Ding W. HDAC inhibitor sodium butyrate augments the MEF2C enhancement of Namp expression under hypoxia. Current pharmaceutical design. 2014; 20(11):1604–13. Epub 2013/07/31. PMID: 23888946.

18. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation. 2014; 124(1):30–9. Epub 2014/01/03. doi: 10.1172/JCI69738 PMID: 24382387; PubMed Central PMCID: PMC3871231.

19. Wang LT, Liou JP, Li YH, Liu YM, Pan SL, Teng CM. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKdelta and E-cadherin. Oncotarget. 2014; 5(14):5651–62. Epub 2014/07/13. PMID: 25015091.
20. Tarhini AA, Zahoor H, McLoughlin B, Gooding WE, Schmitz JC, Siegfried JM, et al. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer research. 2013; 33(10):4475–81. Epub 2013/10/15. PMID: 24123018.

21. Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug discoveries & therapeutics. 2013; 7(4):129–36. Epub 2013/09/28. PMID: 24071574.

22. Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, et al. Targeting histone deacetylase in thyroid cancer. Expert opinion on therapeutic targets. 2013; 17(2):179–93. Epub 2012/12/14. doi: 10.1517/14728222.2013.740013 PMID: 23234477.

23. Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. British journal of haematology. 2013; 162(4):559–62. Epub 2013/05/23. doi: 10.1111/bjh.12388 PMID: 23692150.

24. Fortunati N, Marano F, Bandinoo A, Frairia R, Catalano MG, Boccuzzi G. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. International journal of oncology. 2014; 44(3):700–8. Epub 2013/12/25. doi: 10.3892/ijo.2013.2218 PMID: 24366407.

25. Xu M, Hong M, Xie H. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation. Nan yì yí de xue bao = Journal of Southern Medical University. 2013; 33(10):1409–15. Epub 2013/10/23. PMID: 24144737.

26. Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PloS one. 2013; 8(8):e74253. Epub 2013/08/31. doi: 10.1371/journal.pone.0074253 PMID: 23991216; PubMed Central PMCID: PMC3753304.

27. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma research. 2013. Epub 2013/08/22. doi: 10.1097/CMR.0b013e328364c0ed PMID: 23963286.

28. Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PloS one. 2013; 8(9):e76662. Epub 2013/10/08. doi: 10.1371/journal.pone.0076662 PMID: 24098799; PubMed Central PMCID: PMC3786928.

29. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Molecular cancer. 2013; 12(1):114. Epub 2013/10/08. doi: 10.1186/1476-4598-12-114 PMID: 24093956; PubMed Central PMCID: PMC3855770.

30. Jeon YJ, Ko SM, Cho JH, Chae JI, Shim JH. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expression of specificity protein 1 in oral squamous cell carcinoma. International journal of molecular medicine. 2013; 32(4):860–6. Epub 2013/07/24. doi: 10.3892/ijmm.23977235.

31. Ma YY, Lin H, Moh JS, Chen KD, Wang JW, Ou YC, et al. Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwanese journal of obstetrics & gynecology. 2011; 50(2):165–71. Epub 2011/07/28. doi: 10.1016/j.tjog.2011.01.022 PMID: 21791302.

32. de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, et al. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013; 8(8):1091. Epub 2013/07/17. doi: 10.1097/JTO.0b013e318293d88c PMID: 23857399.

33. Darzykiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods. 2008; 44(3):250–4. Epub 2008/03/04. doi: 10.1016/j.ymeth.2007.11.008 PMID: 18314056; PubMed Central PMCID: PMC2295206.

34. Yu G, Yao W, Wang J, Ma X, Xiao W, Li H, et al. LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PloS one. 2012; 7(8):e42377. Epub 2012/08/11. doi: 10.1371/journal.pone.0042377 PMID: 22879955; PubMed Central PMCID: PMC3239322.

35. Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug discoveries & therapeutics. 2013; 7(4):129–36. Epub 2013/09/28. PMID: 24071574.

36. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2005; 113(4):264–8. Epub 2005/05/04. doi: 10.1111/j.1600-0463.2005.apm_04.x PMID: 15865607.
37. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Annals of the New York Academy of Sciences. 2003; 983:220–31. Epub 2003/05/02. PMID: 12724227.

38. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer cell. 2004; 5(5):455–63. Epub 2004/05/18. PMID: 15144953.

39. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(6):1669–77. Epub 2008/03/19. doi: 10.1185/1078-0432.CCR-07-0990 PMID: 18347167.

40. Gotze S, Coersmeyer M, Muller O, Sievers S. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells. International Journal of Oncology. 2014. Epub 2014/07/23. doi: 10.3892/ijo.2014.2550 PMID: 25050608.

41. Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS one. 2011; 6(3):e18087. Epub 2011/04/06. doi: 10.1371/journal.pone.0018087 PMID: 21464950; PubMed Central PMCID: PMC3664594.

42. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery. 2006; 5(9):769–84. Epub 2006/09/07. doi: 10.1038/nrd2133 PMID: 16955068.

43. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncology reports. 2007; 18(4):769–74. Epub 2007/09/06. PMID: 17766534.

44. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(1):91–9. Epub 2009/01/02. doi: 10.1158/1078-0432.CCR-08-0684 PMID: 19118036.

45. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & lymphoma. 2006; 49(3):502–7. Epub 2008/02/26. doi: 10.1080/10428190701817258 PMID: 18297527.

46. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2008; 19(8):1564–9. Epub 2008/02/26. doi: 10.1093/annonc/mdn031 PMID: 18296419.

47. Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-negative lymphoblastic leukemia cells. Blood. 2008; 111(10):5093–100. Epub 2008/03/20. doi: 10.1182/blood-2007-10-117782 PMID: 18349321; PubMed Central PMCID: PMC2384136.

48. Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, et al. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS one. 2013; 8(9):e73401. Epub 2013/09/12. doi: 10.1371/journal.pone.0073401 PMID: 24023871; PubMed Central PMCID: PMC3762759.

49. Ghozrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013; 121(8):1296–303. Epub 2013/01/05. doi: 10.1182/blood-2012-06-439307 PMID: 23288781; PubMed Central PMCID: PMC3579851.

50. Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, et al. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(19):6264–73. Epub 2008/07/03. doi: 10.1158/1078-0432.CCR-07-1452 PMID: 18829507.

51. Xu M, Knox AJ, Michaelis KA, Kiseljak-Vassiliades K, Kleinschmidt-DeMasters BK, Lillehei KO, et al. Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology. 2012; 153(7):2963–73. Epub 2012/05/09. doi: 10.1210/en.2011-2021 PMID: 22562171.

52. Bernal C, Aguayo F, Villarreal C, Vargas M, Diaz I, Ossandon FJ, et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(19):6264–9. Epub 2008/10/03. doi: 10.1158/1078-0432.CCR-07-4522 PMID: 18829507.

53. Beasley WD, Beynon J, Jenkins GJ, Parry JM. Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study. International
54. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. The Journal of biological chemistry. 2000; 275 (30):22627–30. Epub 2000/08/10. doi: 10.1074/jbc.C000235200 PMID: 10930422.

55. Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Molecular cancer research: MCR. 2013; 11(11):1362–74. Epub 2013/08/29. doi: 10.1158/1541-7786.MCR-13-0091 PMID: 23982217.